The 340B Drug Pricing Program Still Has Untapped Potential at Most Expansion Entities

The 340B Drug Pricing Program delivers real value for covered entities. For expansion entity hospitals, that value includes orphan drug savings that most facilities never fully capture. Structured management of designations, indications, and manufacturer pricing is the difference. Dr. Lisa Nezneski has helped recover over USD 500 million.